Lake Street starts Organogenesis with Buy on competitive advantages

Lake Street analyst Brooks O’Neil initiated coverage of Organogenesis with a Buy rating and $5 price target. Organogenesis is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical & sports medicine markets, the analyst tells investors in a research note. The firm says the company has a solid, clinically proven product line and a promising pipeline that might include a potential blockbuster for knee osteoarthritis. Lake models Organogenesis’ 2024 towards the low end of guidance and sees little growth for 2025, but believes the company’s “strong” brand equity, established commercial infrastructure, and plans to establish clinical validation to secure coverage for key commercialized products “represent substantial competitive advantages.”